# Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers

> **NCT04019743** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Hypertension
- Dyslipidemias

## Interventions

- **DRUG:** CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
- **DRUG:** CKD-333 16/10/40mg formulation 1 Tab. 1T
- **DRUG:** CKD-333 16/10/40mg formulation 2 Tab. 1T

## Key facts

- **NCT ID:** NCT04019743
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-28
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-09-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019743, "Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04019743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*